ABNX 100
Alternative Names: ABNX-100Latest Information Update: 03 Nov 2023
At a glance
- Originator ABIONYX Pharma
- Class Apolipoprotein therapeutics; Eye disorder therapies; Phospholipids; Recombinant proteins
- Mechanism of Action Apolipoprotein A-I replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Uveitis